Compare · head to head
Invivyd vs Medpaces
Medpaces ranks higher overall — 360 rank 96 vs 40.
Medpaces leads on Quality (83 vs 47), Growth (64 vs 45) and Safety (63 vs 36). Invivyd leads on Sentiment (62 vs 43). The two are close on Value.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Life Sciences Tools & Services |
| Size | Small | Large |
| ISIN | US00534A1025 | US58506Q1094 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 40 | 96 |
| Value | 50 | 54 |
| Quality | 47 | 83 |
| Growth | 45 | 64 |
| Safety | 36 | 63 |
| Sentiment | 62 | 43 |
| Quality details | ||
| Profitability | 47 | 95 |
| Cash Truth | 47 | 71 |
Invivyd vs Vera TherapeuticsInvivyd vs Seres TherapeuticsInvivyd vs BIOAGE LabsInvivyd vs Dianthus TherapeuticsAdd a third stock →
Full analyses: Invivyd · Medpaces
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100